Antibody response to postexposure prophylaxis in infants born to hepatitis B surface antigen-positive women

Pediatric Infectious Disease Journal

Volumn 22, Issue 2, 2003, Pages 123-129

  Euler, Gary L ^a,b   Copeland, John R ^a   Rangel, Maria C ^a   Williams, Walter W ^b  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Antibody to hepatitis B surface antigen; Hepatitis B surface antigen positive women; Hepatitis B vaccination; Infant

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; DELIVERY; HEPATITIS B; HEPATITIS B VIRUS; HOME DELIVERY; HOUSEHOLD; HUMAN; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; INCOME; INFANT; INFECTION PREVENTION; LIVER CANCER; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; NEWBORN; PATIENT CARE; PERINATAL CARE; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; RISK ASSESSMENT; SEROLOGY; VACCINATION;

CONFIDENCE INTERVALS; DISEASE TRANSMISSION, VERTICAL; FEMALE; FOLLOW-UP STUDIES; HEALTH SURVEYS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; INFANT, NEWBORN; MALE; MATERNAL-FETAL EXCHANGE; MULTIVARIATE ANALYSIS; ODDS RATIO; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRIMARY PREVENTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VACCINATION;

EID: 0037323531     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200302000-00007     Document Type: Article

References (47)

1. CDC. Hepatitis surveillance report. Atlanta: Centers for Disease Control and Prevention, 1995;56:1-36.
2. Shapiro, CN, Margolis, HS. Impact of hepatitis B virus infection on women and children. Infect Dis Clin North Am 1992;6:75-96.
3. Maynard, JE, Kane, MA, Hadler, SC. Global control of hepatitis B through vaccination: role of hepatitis B vaccine in the expanded program on immunization. Rev Infect Dis 1989;11(Suppl 3):574-8.
4. Margolis, HS, Alter, MJ, Hadler, SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991;11:84-92.
5. CDC. Recommendation of the Immunization Practices Advisory Committee (ACIP) inactivated hepatitis B virus vaccine. MMWR 1982;31:317-22, 327-8.
6. CDC. Protection against viral hepatitis: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1990;39(RR-2):1-26.
7. Stevens CE, Toy PT, Tong MJ, et al. Perinatal hepatitis B virus transmission in the United States: prevention by passive-active immunization. JAMA 1985;253:1740-5.
8. Stevens CE, Taylor PE, Tong MJ, et al. Yeast-recombinant hepatitis B vaccine: efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 1987;257:2612-6.
9. Xu ZY, Liu CB, Francis DP, et al. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics 1985;76:713-8.
10. Steel RDG, Torrie JH. Principles and procedures of statistics. New York: McGraw-Hill, 1960:15.
11. McCullagh P. Regression models for ordinal data (with discussion). J R Statist Soc B 1980;42:109-42.
12. SAS Version 8.02, 1999-2001. Cary, NC: SAS Institute, 2001.
13. CDC. Prevention of perinatal hepatitis B through enhanced case management: Connecticut, 1994-95, and United States, 1994. MMWR 1996;45:584-7.
14. Roome A, Rak M, Hadler J. Follow-up of infants of hepatitis B-infected women after hepatitis B vaccination, Connecticut, 1994 to 1997. Pediatr Infect Dis J 2000;19:573-5.
15. Marion SA, Pastore MT, Pi DW, Mathias RG. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol 1994;140:734-46.
16. Kohn MA, Farley TA, Scott C. The need for more aggressive follow-up of children born to hepatitis B surface antigen-positive mothers: lessons from the Louisiana Perinatal Hepatitis B Immunization Program. Pediatr Infect Dis J 1996;15:535-40.
17. CDC. Program to prevent perinatal hepatitis B virus transmission in a health-maintenance organization: Northern California, 1990-1995. MMWR 1997;46:378-80.
18. Ikeda RM, Birkhead GS, Flynn MK, Thompson SF, Morse DL. Use of multiple reporting sources for perinatal hepatitis B surveillance and follow-up. Am J Epidemiol 1995;142:765-70.
19. Osterholm MT. Hepatitis B infection in Minnesota: a case for universal immunization. Pediatr Infect Dis J 1998;17(Suppl):S30-4.
20. Wu JS, Hwang LY, Goodman KJ, Beasley RP. Hepatitis B vaccination in high-risk infants: 10-year follow-up. J Infect Dis 1999;179:1319-25.
21. Goldgarb J, Medendorp SV, Garcia H, Nagamori K, Rathfon H, Krause D. Comparison study of the immunogenicity and safety of 5- and 10-μg dosages of recombinant hepatitis B vaccine in healthy infants. Pediatr Infect Dis J 1996;15:764-7.
22. Greenberg DP, Vadheim CM, Wong VK, et al. Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age. Pediatr Infect Dis J 1996;15:590-6.
23. Inskip HM, Hall AJ, Chotard J, Loik F, Whittle H. Hepatitis B vaccine in the Gambian Expanded Programme on Immunization: factors influencing antibody response. Int J Epidemiol 1991;20:764-9.
24. Zajac BA, West DJ, McAleer WJ, Scolnick EM. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect 1986;13(Suppl A):39-45.
25. Stevens CE, Toy PT, Taylor PE, Lee T, Yip HY. Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long-term protection. Pediatrics 1992;90:170-3.
26. Krugman S, Davidson M. Hepatitis B vaccine: prospects for duration of immunity. Yale J Biol Med 1987;60:333-8.
27. Jilg W, Schmidtr M, Deinhardt R. Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis 1989;160:766-9.
28. Goh KT, Tan KL, Kong KH, Oon CJ, Chan SH. Comparison of the immune response of four different dosages of a yeast recombinant hepatitis B vaccine in Singapore children: a four year follow-up study. Bull WHO 1993;70:233-9.
29. Chotard J, Inskip HM, Hall AJ, et al. The Gambia hepatitis intervention study: follow-up of a cohort of children vaccinated against hepatitis B. J Infect Dis 1992;166:764-8.
30. Alaimo K, Olson CM, Frongillo EA Jr, Briefel RR. Food insufficiency, family income, and health in US preschool and school-aged children. Am J Public Health 2001;91:781-6.
31. Casey PH, Szeto K, Lensing S, Bogle M, Weber J. Children in food-insufficient, low-income families: prevalence, health, and nutrition status. Arch Pediatr Adolesc Med 2001;155:508-14.
32. Haskell MJ, Brown KH. Maternal vitamin A nutriture and the vitamin A content of human milk. J Mammary Gland Neoplasia 1999;4:243-57.
33. Kim I, Hungerford DW, Yip R, Kuester SA, Zyrkowski C, Trowbridge FL. Pregnancy nutrition surveillance system: United States, 1979-1990. MMWR 1992;41:25-41.
34. Franz KB. Magnesium intake during pregnancy. Magnesium 1987;6:18-27.
35. Chandra S, Chandra RK. Nutrition, immune response, and outcome. Prog Food Nutr Sci 1986;10:1-65.
36. Vobecky JS. Nutritional aspects of preconceptional period as related to pregnancy and early infancy. Prog Food Nutr Sci 1986;10:205-36.
37. Snowman MK. Nutrition component in a comprehensive child development program: II. Nutrient intakes of low-income, pregnant women and the outcome of pregnancy. J Am Dietetic Assoc 1979;74:124-9.
38. Duggan C. Micronutrients and infections: the road from A to Z and beyond. J Pediatr Gastroenterol Nutr 2000;31:467.
39. Oon CJ, Lim GK, Ye Z, et al. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 1995;13:699-702.
40. Tang JR, Hsu HY, Lin HH, Ni YH, Chang MH. Hepatitis B surface antigenemia at birth: a long-term follow-up study. J Pediatr 1998;133:374-7.
41. Lin HH, Ohto H, Etoh T, Yoneyama T, Kawana T, Mizuno M. Studies on the risk factors of intrauterine infection of hepatitis B virus. Acta Obstet Gynaecol Jpn 1985;37:2393-400.
42. Lee SD, Lo KJ, Wu JC, et al. Prevention of maternal-infant hepatitis B virus transmission by immunization: the role of serum hepatitis B virus DNA. Hepatology 1986;6:369-73.
43. Ngui SL, Andrews NJ, Underhill GS, Heptonstall J, Teo CG. Failed postnatal immuno-prophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors. Clin Infect Dis 1998;27:100-6.
44. Tan KL, Goh KT, Oon CJ, Chan SH. Immunogenicity of recombinant yeast-derived hepatitis B vaccine in nonresponders to perinatal immunization. JAMA 271:859-61.
45. Lazizi Y, Badur S, Perk Y, Ilter O, Pillot J. Selective unresponsiveness to HBsAg vaccine in newborns related with an in utero passage of hepatitis B virus DNA. Vaccine 1997;15:1095-100.
46. del Canho R, Grosheide PM, Mazel JA, et al. Ten-year neonatal hepatitis B vaccination program, the Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 1997;15:1624-30.
47. Vranckx R, Alisjahbana A, Meheus A. Hepatitis B virus vaccination and antenatal transmission of HBV markers to neonates. J Viral Hepatitis 1999;6:135-9.